A case of migraine headache successfully treated with low-dose magnesium phosphate in a pregnant woman
Abstract
Magnesium supplementation is considered to be a safer and effective alternative to conventional drugs in the treatment and prevention of migraine headache. Trials to date demonstrate beneficial outcomes at low and higher doses. Higher doses, however, are associated with more adverse events. It is not clear how low-dose magnesium phosphate works, particularly in light of the fact that it isn't clear if the supplement is bioavailable. A case is presented where a pregnant woman with recurring migraines was successfully treated with magnesium phosphate. The precautionary approach influenced the choice of this low-dose magnesium supplement as there are reasons to believe that excessive doses of magnesium may be deleterious in pregnancy, particularly towards the developing foetus. Energetic or placebo effects need to be considered in the interpretation of this outcome.
Read the paper
Related studies
- Bioactive Molecules Released in Food by Lactic Acid Bacteria: Encrypted Peptides and Biogenic Amines
- A central role for amyloid fibrin microclots in long COVID/PASC: origins and therapeutic implications
- Bioaccessibility and bioavailability of phenolic compounds
- The Glutamate Hypothesis in ALS: Pathophysiology and Drug Development
- Therapeutic Approaches to Genetic Ion Channelopathies and Perspectives in Drug Discovery
- Effects of the Mediterranean Diet on the Components of Metabolic Syndrome Concerning the Cardiometabolic Risk
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.